Halozyme Therapeutics, Inc.
HALO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $9 | $6 | $8 | $6 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $2 | $2 | $2 | $2 |
| Enterprise Value | $10 | $8 | $9 | $7 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 8.8% | 23% | -11.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 84.4% | 85.8% | 81.7% | 85.9% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 80.3% | 70.6% | 63.7% | 68.2% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 49.5% | 50.7% | 44.6% | 46% |
| EPS Diluted | 1.43 | 1.33 | 0.93 | 1.06 |
| % Growth | 7.5% | 43% | -12.3% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |